PDCD1 and cancer: Cancer immunotherapy using immune checkpoint blockade (ICB) inhibitors (e.g., anti-PD-1/PD-L1 and anti-CTLA-4 antibodies) has achieved remarkable clinical success, yielding durable and long-term therapeutic responses in multiple cancer types1.